Journal of the Bahrain Medical Society
Year 2021, Volume 33, Issue 4, Pages 19-23
https://doi.org/10.26715/JBMS.33_2021_4_5Tarique S. Chachar1, Nooraldaem Yousif2, Khurshid Ahmed3, Tajammul Hussain4, Haitham Amin5*
1Senior Resident, Department of Cardiology, Mohammed bin Khalifa bin Sulman Al-Khalifa Specialist Cardiac Centre (MKCC), Bahrain.
2Consultant Interventional Cardiologist, Mohammed bin Khalifa bin Sulman Al-Khalifa Specialist Cardiac Centre (MKCC), Bahrain.
3Senior Resident, Mohammed bin Khalifa bin Sulman Al-Khalifa Specialist Cardiac Centre (MKCC), Bahrain.
4Chief Resident, Mohammed bin Khalifa bin Sulman Al-Khalifa Specialist Cardiac Centre (MKCC), Bahrain.
5Consultant Interventional Cardiologist, Department of Cardiology, Mohammed bin Khalifa bin Sulman Al-Khalifa Specialist Cardiac Centre (MKCC), Bahrain.
*Corresponding author: HaithamAmin,MD, FRCPC, FACC, FSCAI,Consultant Interventional Cardiologist, Department of Cardiology, Mohammed bin Khalifa bin Sulman Al-Khalifa Specialist Cardiac Centre (MKCC), Kingdom of Bahrain, E-mail: Haitham_amin@yahoo.com. Tel: + (973) 39449889
Received date: July 7, 2021; Accepted date: August 10, 2021; Published date: December 31, 2021
Abstract
Left ventricular thrombus (LVT) is a known complication of acute myocardial infarction (AMI). Vitamin K antagonists such as Warfarin showed a reduction in associated mortality and morbidity and are indicated as anticoagulants of choice in current guidelines. Since their approval for clinical use, there has been a dramatic increase in off-label use of direct oral anti-coagulants (DOAC) for LVT. In this case series, the authors share their successful experience with DOAC in the treatment of LVT.
Keywords: Anti-coagulants, Heart diseases, Heart ventricles, Myocardial infarction, Thrombosis